Mark Alan Goldberg Blueprint Medicines Corp (BPMC) insider trading activity

Mark Alan Goldberg is of Blueprint Medicines Corp. Currently has a direct ownership of 18,254 shares of BPMC, which is worth approximately $1.65 Million. The most recent transaction as insider was on Jun 12, 2024, when has been sold 2,242 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 18.3K

0% 3M change

14.0% 12M change

Total Value Held $1.65 Million

Mark Alan Goldberg Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 12 2024	BUY Grant, award, or other acquisition	-	2,242 Added 10.94%	18,254 Common Stock
Jun 21 2023	BUY Grant, award, or other acquisition	-	2,600 Added 13.97%	16,012 Common Stock
Jun 21 2022	BUY Grant, award, or other acquisition	-	2,600 Added 16.24%	13,412 Common Stock
Mar 03 2022	BUY Open market or private purchase	$299,900 $59.98 p/Share	5,000 Added 31.62%	10,812 Common Stock
Jun 02 2021	BUY Grant, award, or other acquisition	-	2,250 Added 27.91%	5,812 Common Stock
Dec 24 2020	SELL Open market or private sale	$681,875 $125.0 p/Share	5,455 Reduced 60.5%	3,562 Common Stock
Dec 24 2020	BUY Exercise of conversion of derivative security	$153,558 $28.15 p/Share	5,455 Added 37.69%	9,017 Common Stock
Dec 18 2020	SELL Open market or private sale	$654,480 $120.0 p/Share	5,454 Reduced 60.49%	3,562 Common Stock
Dec 18 2020	BUY Exercise of conversion of derivative security	$153,530 $28.15 p/Share	5,454 Added 37.69%	9,016 Common Stock
Dec 11 2020	SELL Open market or private sale	$627,325 $115.0 p/Share	5,455 Reduced 60.5%	3,562 Common Stock
Dec 11 2020	BUY Exercise of conversion of derivative security	$153,558 $28.15 p/Share	5,455 Added 37.69%	9,017 Common Stock
Dec 01 2020	SELL Open market or private sale	$599,940 $110.0 p/Share	5,454 Reduced 60.49%	3,562 Common Stock
Dec 01 2020	BUY Exercise of conversion of derivative security	$153,530 $28.15 p/Share	5,454 Added 37.69%	9,016 Common Stock
Oct 19 2020	SELL Open market or private sale	$572,775 $105.0 p/Share	5,455 Reduced 60.5%	3,562 Common Stock
Oct 19 2020	BUY Exercise of conversion of derivative security	$106,536 $19.53 p/Share	5,455 Added 37.69%	9,017 Common Stock
Oct 07 2020	SELL Open market or private sale	$545,400 $100.0 p/Share	5,454 Reduced 60.49%	3,562 Common Stock
Oct 07 2020	BUY Exercise of conversion of derivative security	$106,517 $19.53 p/Share	5,454 Added 37.69%	9,016 Common Stock

Also insider at

IMGN

ImmunoGen, Inc. Healthcare

Director

IDRA

IDERA PHARMACEUTICALS, INC. Healthcare

GLYC

GLYCOMIMETICS INC Healthcare

MAG